AstraZeneca Returns Worldwide Rights to IPI-504 and IPI-493 Development Programs to Infinity Pharmaceuticals
News Dec 15, 2008
AstraZeneca has announced that it has returned worldwide rights to Infinity Pharmaceuticals for the development and commercialization of Infinity’s heat shock protein 90 (Hsp90) drug candidates IPI-504 (MEDI-561) and IPI-493, in development for the treatment of cancer and related conditions.
The collaboration, initiated in August 2006 between MedImmune and Infinity, was transferred to AstraZeneca following its acquisition of MedImmune in June 2007.
After reviewing the potential opportunity for these projects within its portfolio and considering competing R&D investment priorities, AstraZeneca has decided to return the responsibility for development and commercialization of this program to Infinity.
Infinity is fully committed to targeting Hsp90 as a potential new treatment approach to cancer, and to developing both IPI-504 and IPI-493.
In particular, Infinity initiated a late stage trial of IPI-504 in patients with refractory gastrointestinal stromal tumors (GIST), a rare tumor of the gastrointestinal tract. IPI-504 and IPI-493 are in additional late- and early-stage ongoing clinical trials.